Aclasta: Postmarketing study started

Earlier this year, Novartis began a single-arm, open-label, German postmarketing trial to evaluate 4 mg IV zoledronic acid every 4 weeks for 3 months in about 60 castration-resistant prostate cancer (CRPC) patients with bone metastasis. Novartis markets zoledronic acid as Reclast in the U.S and as Aclasta in the EU to treat osteoporosis in postmenopausal women at increased risk of fracture and to treat Paget's disease. The pharma also markets the product as Zometa in the U.S. and EU to treat bone metastases and bone complications in cancer patients. ...